Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center [0.03%]
芬兰三级医疗中心治疗慢性淋巴细胞白血病患者的真实世界治疗和结局特征分析
Juha Ranti,Katariina Perkonoja,Tommi Kauko et al.
Juha Ranti et al.
Objectives: We conducted this retrospective study to characterize the change in chronic lymphocytic leukemia (CLL) treatment patterns between 2005 and 2019, to understand the treatment sequencing across the course of the ...
Optimal time and threshold of absolute lymphocyte count recovery as a prognostic factor after single-unit cord blood transplantation in adults [0.03%]
单个脐血移植后成人淋巴细胞绝对值计数的理想恢复时间及阈值与预后的相关性研究
Takaaki Konuma,Maki Monna-Oiwa,Kosuke Takano et al.
Takaaki Konuma et al.
We retrospectively evaluated the optimal time and threshold of absolute lymphocyte count (ALC) recovery as a prognostic factor in 174 adult patients who received single-unit cord blood transplantation (CBT) at our institute. We analyzed the...
A rare der(10)t(X;10)(p11.2;p11.2) in an elderly patient with therapy-related acute myelomonocytic leukemia [0.03%]
老年继发性急性髓单核细胞白血病患者罕见的der（10）t（X；10）（p11.2;p11.2）染色体异常
Masahiro Manabe,Nao Tanizawa,Satoru Nanno et al.
Masahiro Manabe et al.
Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review [0.03%]
老年/体弱患者套细胞淋巴瘤治疗选择的系统性综述
Tahera Alnassfan,Megan J Cox-Pridmore,Azzam Taktak et al.
Tahera Alnassfan et al.
Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma (NHL) that is aggressive and incurable with existing therapies, presenting a significant unmet clinical need. MCL occurs mainly in elderly patients with comorbidities; thus, i...
Corrigendum [0.03%]
勘误表
[This corrects the article DOI: 10.1002/jha2.37.]. © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Published Erratum
EJHaem. 2021 Nov 24;3(1):314. DOI:10.1002/jha2.345 2021
Isolated skin infiltration by a blastic plasmacytoid dendritic cell neoplasm [0.03%]
孤立的浆细胞样树突状细胞肿瘤皮肤浸润病灶
Grégoire Stalder,Dina Milowich,Sabine Blum et al.
Grégoire Stalder et al.
Leg-type form of idiopathic multicentric Castleman disease associated with severe lower extremity chronic venous/lymphatic disease [0.03%]
与严重下肢慢性静脉和淋巴疾病相关的难治性多中心型Castleman病腿型表现形式
Thomas Ballul,Nabil Belfeki,Adèle de Masson et al.
Thomas Ballul et al.
Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disease of unknown etiology. Deciphering mechanisms involved in CD pathogenesis may help improving patients' care. Six cases of stereotyped sub-diaphragmatic iMCD aff...
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma [0.03%]
塞利尼索、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效
Cristina Gasparetto,Suzanne Lentzsch,Gary Schiller et al.
Cristina Gasparetto et al.
We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combinatio...
First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID-19 in an allogeneic stem cell transplant patient [0.03%]
首例托珠单抗治疗新冠相关细胞因子风暴综合征的异基因移植患者的安全性和有效性的病例报告
Nicholas Fordham,Emma Baker,Daniel Forton et al.
Nicholas Fordham et al.
Joshua Mortimer,Nicola Gray,Michael Desborough et al.
Joshua Mortimer et al.
This is a case of an unexpected and dramatic bleeding complication in a patient post-bone marrow biopsy performed for investigation of an IgA paraprotein with the results confirming multiple myeloma. Subsequent investigations were suggestiv...